Any current/future new fundraising through debt or equity?

Currently, there is no mention of any ongoing or planned fundraising through debt or equity. The company has put major Capex plans on hold to avoid burdening cash flow during difficult times. Future Capex decisions, including investments in additional manufacturing capacity, will be taken cautiously after stabilizing profitability and margins. Any large investments or capacity expansions will be evaluated and decided by the board at appropriate times. No specific plans for raising funds via equity or debt have been disclosed for FY25 or FY26.

Any current/future capex/capital investment/strategic investment?

Current Capex is on hold to avoid burdening cash flow during difficult times; focus is on stabilizing existing business first. Planned Capex for FY25 includes ₹1.5 to 2 crores to repurpose existing manufacturing facilities for a new product (modification and debottlenecking). Major Capex proposals (formulation plant and intermediate plant with ~2000 tons capacity) have been deferred to FY26 or beyond, pending profitability and margin improvement. Two new formulation plants have been acquired; setting up of a new formulation plant expected next year to add capacity, not to shift existing plant.

Future growth expectations in sales/revenue/volumes?

Target revenue for FY26: Over ₹210 crore (Ashit Dave on Q4 and FY26 outlook). Brand business revenue target for FY26: ₹200 crore (aim to double in two years). Volume growth expectation: 15-20% increase year-on-year. Export to domestic sales ratio currently ~50:50, with expectation of export business improvement in FY26. New products: Three recently commercialized molecules expected to generate significant revenue from next financial year. Capacity utilization: Currently around 70%, with plans to repurpose insecticide plant and consider additional capacity in Q4 FY25. Bifenthrin capacity to be

Future growth expectations in earnings/operating earnings/profits/EPS?

Aimco Pesticides expects to be profitable by the end of FY25, with improving Q3 and Q4 performance. Revenue target for FY25 is over ₹210 crore, with EBITDA margins expected to improve, though Q4 pricing remains uncertain. For FY26, a clearer revenue and EBITDA margin target will be shared next quarter; branded business aims for ₹200 crore revenue by FY26. The company plans 15-20% volume growth annually over the next couple of years, aided by new product launches and export market expansion. Gross margins for branded formulations are stable at 30-35%, with EBITDA margins around 10%, expected to

Current/ Expected Orderbook/ Pending Orders?

Significant orders are ongoing in Q3, with volume-wise expectations being satisfactory. Q4 order projections are uncertain due to pricing and supply issues, especially from China. Negotiations for new export contract products, including a herbicide, are ongoing but not finalized. Discussions for Bifenthrin volumes in Brazil are active, expecting significant volume in Q4 and full capacity utilization by FY26. Three new products are commercialized and early stage sales have started; significant ramp-up expected in next financial year. The company's export orderbook faces pressure from price eros

Aimco Pesticides LtdQ2 FY25Fertilizers & Agrochemicals

Aimco Pesticides Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹39.24Market Cap: ₹38 CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Target revenue for FY26: Over ₹210 crore (Ashit Dave on Q4 and FY26 outlook).
Brand business revenue target for FY26: ₹200 crore (aim to double in two years).
Volume growth expectation: 15-20% increase year-on-year.
Export to domestic sales ratio currently ~50:50, with expectation of export business improvement in FY26.
New products: Three recently commercialized molecules expected to generate significant revenue from next financial year.
Capacity utilization: Currently around 70%, with plans to repurpose insecticide plant and consider additional capacity in Q4 FY25.
Bifenthrin capacity to be fully utilized in next two financial years, driven by Brazil market entry.
Overall growth dependent on pricing, market conditions, and regulatory registrations, especially in Brazil.
EBITDA margin expected to remain stable or improve with new high-margin branded products.

Margin guidance

Category 3

Aimco Pesticides expects to be profitable by the end of FY25, with improving Q3 and Q4 performance.
Revenue target for FY25 is over ₹210 crore, with EBITDA margins expected to improve, though Q4 pricing remains uncertain.
For FY26, a clearer revenue and EBITDA margin target will be shared next quarter; branded business aims for ₹200 crore revenue by FY26.
The company plans 15-20% volume growth annually over the next couple of years, aided by new product launches and export market expansion.
Gross margins for branded formulations are stable at 30-35%, with EBITDA margins around 10%, expected to sustain as product mix improves.
New products commercial ramp-up and export registrations (e.g., Triclopyr in Brazil in FY26) should enhance growth.
Capex remains cautious to preserve cash flow, focusing on repurposing existing plants for new products with major capacity expansions deferred till profitability stabilizes.

See what Aimco Pesticides Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Currently, there is no mention of any ongoing or planned fundraising through debt or equity.
The company has put major Capex plans on hold to avoid burdening cash flow during difficult times.
Future Capex decisions, including investments in additional manufacturing capacity, will be taken cautiously after stabilizing profitability and margins.
Any large investments or capacity expansions will be evaluated and decided by the board at appropriate times.
No specific plans for raising funds via equity or debt have been disclosed for FY25 or FY26.

Order book

Significant orders are ongoing in Q3, with volume-wise expectations being satisfactory.
Q4 order projections are uncertain due to pricing and supply issues, especially from China.
Negotiations for new export contract products, including a herbicide, are ongoing but not finalized.
Discussions for Bifenthrin volumes in Brazil are active, expecting significant volume in Q4 and full capacity utilization by FY26.
Three new products are commercialized and early stage sales have started; significant ramp-up expected in next financial year.
The company's export orderbook faces pressure from price erosion and competition but volume remains steady.
Domestic brand business order momentum is strong and growing with expected revenue of ₹130 crore for FY25 and ₹200 crore by FY26.
Additional capacity decisions for new molecules pending and to be finalized next quarter.

See what Aimco Pesticides Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Current Capex is on hold to avoid burdening cash flow during difficult times; focus is on stabilizing existing business first.
Planned Capex for FY25 includes ₹1.5 to 2 crores to repurpose existing manufacturing facilities for a new product (modification and debottlenecking).
Major Capex proposals (formulation plant and intermediate plant with ~2000 tons capacity) have been deferred to FY26 or beyond, pending profitability and margin improvement.
Two new formulation plants have been acquired; setting up of a new formulation plant expected next year to add capacity, not to shift existing plant.
Additional capacity decisions for three new molecules will be made in Q4 FY25 based on market conditions.
Large-scale capacity expansions for new products anticipated in FY26 after product registrations and market demand improve.
Board to evaluate and approve any major future plant capacity investments carefully.

Track Aimco Pesticides Ltd — get its next earnings analysis in your feed

How does Aimco Pesticides Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

ThisAimco Pesticides Ltd

Rev 3Mar 3

See where Aimco Pesticides Ltd sits in Fertilizers & AgrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Aimco Pesticides Ltd rank in Fertilizers & Agrochemicals?

Compare Aimco Pesticides Ltd against every Fertilizers & Agrochemicals company (Q2 FY25) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

What Aimco Pesticides Ltd's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season

Dhanuka Agritech Ltd (Q2 FY27)
657.51 Crores . Key investor presentation takeaways from Dhanuka Agritech Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
Sharda Cropchem Ltd (Q2 FY27)
1,051.7 Cr, up 13% YoY (Q2 FY26: Rs. Key investor presentation takeaways from Sharda Cropchem Ltd's Q2 FY27 investor presentation — and how it ranks against sec
Paradeep Phosphates Ltd (Q2 FY27)
Revenue from operations for the quarter ended 30 September 2026: Rs 7,164.06 crores . Key results statement takeaways from Paradeep Phosphates Ltd's Q2 FY27 ear
Astec Lifescienc (Q2 FY27)
2.3% YoY decline. Key results statement takeaways from Astec Lifescienc's Q2 FY27 results statement — and how it ranks against sector peers.

Compare:vs Coromandel Inter vs UPL Ltd vs F A C T

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Aimco Pesticides Ltd Q2 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Aimco Pesticides Ltd rank in Fertilizers & Agrochemicals?

Continue your research

What Aimco Pesticides Ltd's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season